Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | -$3.33M | -$2.97M |
| Net income | -$3.55M | -$10.2M |
| EPS (diluted) | -$0.20 | -$0.43 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$1.45M | -$9.96M |
| Capital expenditures | — | $13.1K |
| Free cash flow | — | -$9.98M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Total assets | $5.41M | $513K |
| Total liabilities | $24.7M | $10.3M |
| Shareholders' equity | -$19.3M | -$9.81M |
| Retained earnings | -$28.7M | -$38.9M |
| Shares (wtd avg diluted) | 17.5M | 23.8M |
Every figure is extracted from Liminatus Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.